COMPARE · Reviewed July 2, 2026
CPRX vs DOCS
Verdict: Side-by-side breakdown using the Bull Rankings model. CPRX scored 84.4, DOCS scored 90.2 — DOCS ahead by 5.799999999999997.
CPRX
Catalyst Pharmaceuticals, Inc.
84.4
$31.45
Score gap
5.799999999999997
DOCS leads
DOCS
Doximity, Inc.
90.2
$21.86
The companies
CPRXCatalyst Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $3.9b. 3% off the 52-week high of $32.56. Revenue growing +20%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $31.67 (implying +1% upside).
Moat
Net margin 37% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
DOCSDoximity, Inc.
Why now
Health Information Services · market cap $4.0b. Down 71% from 52-week high of $76.51 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Buy with a mean 1-yr target of $24.37 (implying +11% upside).
Moat
Net margin 30% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 167% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 71% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Base grades (each contributes ~14.3% of base composite)
| CPRX | Component | DOCS |
|---|---|---|
| C65 | FCF | C65 |
| B+85 | Rev | B+85 |
| A95 | D/E | A95 |
| A-90 | P/E or P/S | B+85 |
| B+85 | PEG | A-90 |
| Supplemental signals · feed the score, not on the row card | ||
| B+85 | FCF Yield | A-90 |
| A-90 | ROE | A-90 |
| 85.2 | Base composite | 86 |
Adjustments (signed deltas applied on top of base)
CPRX
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
forward P/E cheaper (18 → 10)+1
Total+6
DOCS
compounder synergy (FCF yield ≥5% + ROE ≥15% + D/E <1)+4
GARP sweet spot (PEG <1, positive FCF)+1
insider cluster buying (net +10.4%, 22 txns)+2
forward P/E cheaper (22 → 14)+1
Total+8
DCF cross-check (per-share value vs. live price)
| CPRX upside | Horizon | DOCS upside |
|---|---|---|
| -3% | 1Y | +5% |
| -6% | 5Y | +17% |
| -11% | 10Y | +35% |
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.